Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma

被引:2
|
作者
Turshudzhyan, Alla [1 ]
Hadfield, Matthew [1 ]
Grant-Kels, Jane [1 ]
机构
[1] Univ Connecticut, Dept Internal Med & Dermatol, 263 Farmington Ave, Farmington, CT 06030 USA
关键词
checkpoint inhibitor; immunotherapy; Merkel-cell carcinoma; PD-L1; CASE SERIES; CHEMOTHERAPY; MANAGEMENT; MELANOMA; TARGET; SKIN;
D O I
10.1097/CMR.0000000000000766
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Merkel-cell carcinoma (MCC) is a rare and extremely aggressive nonmelanocytic cutaneous neuroendocrine carcinoma. Historically, it has been associated with limited therapy options and poor prognosis. While its incidence has been rising over the last two decades, recent discoveries and a better understanding of its pathogenesis, viral association and immunologic features have allowed for the emergence of new therapies. Surgical excision with or without radiotherapy remains the first-line therapy for primary lesions without evidence of metastatic disease. The majority of MCC cases are regrettably diagnosed at advanced stages and oftentimes require systemic therapy. There have been several significant advances in the treatment of MCC in the last decade. Among these have been the development of immune checkpoint inhibitors targeting the programmed death protein-1 (PD-1)/programmed death ligand-1 (PDL-1). Despite recent success of immunotherapy, nearly 50% of patients diagnosed with MCC still succumb to the disease. Fortunately, there has been a number of new targeted therapies that hold great promise. Among them are phosphatidylinositide-3kinase (Pl3K) inhibitors, adoptive T-cell immunotherapy, activated NK-92 cells infusions and therapeutic vaccines. Additional emerging therapeutic targets include cellular ubiquitin-specific processing protease 7 (Usp7) that restricts viral replication and IFN genes (STING), activation of which promotes an antitumor inflammatory response.
引用
收藏
页码:421 / 425
页数:5
相关论文
共 50 条
  • [1] Merkel-cell carcinoma: Preoperative clinical diagnosis and therapeutic implications
    Pasta, Vittorio
    Vergine, Massimo
    D'Orazi, Valerio
    Scipioni, Paolo
    Monti, Massimo
    Redler, Adriano
    [J]. ANNALI ITALIANI DI CHIRURGIA, 2014, 85 (04) : 352 - 357
  • [2] Merkel cell carcinoma - current therapeutic options
    Poulsen, M
    Rischin, D
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (12) : 2187 - 2192
  • [3] Merkel-cell carcinoma
    Moll, I.
    [J]. PATHOLOGE, 2019, 40 (Suppl 3): : S350 - S354
  • [4] Merkel-Cell Carcinoma
    Gomez-Arias, Pedro J.
    Salido-Vallejo, Rafael
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (23): : E40 - E40
  • [5] Merkel-cell carcinoma of the skin
    Poulsen, M
    [J]. LANCET ONCOLOGY, 2004, 5 (10): : 593 - 599
  • [6] MERKEL-CELL CARCINOMA OF THE PINNA
    HANNA, GS
    ALI, MH
    AKOSA, AB
    MAHER, EJ
    [J]. JOURNAL OF LARYNGOLOGY AND OTOLOGY, 1988, 102 (07): : 608 - 611
  • [7] More on Merkel-Cell Carcinoma
    Blom, Astrid
    Saiag, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (05): : 494 - 495
  • [8] MERKEL-CELL CARCINOMA OF THE SKIN
    BORTOLANI, A
    BARISONI, D
    COLOMBARI, R
    FURLAN, S
    [J]. PLASTIC AND RECONSTRUCTIVE SURGERY, 1992, 89 (04) : 751 - 754
  • [9] Merkel-cell carcinoma of the upper limb
    Rojoa, Djamila M.
    Katsogridakis, Emmanuel
    Madan, Manmohan
    Rao, Madhu
    [J]. JOURNAL OF SURGICAL CASE REPORTS, 2018, (08):
  • [10] More on Merkel-Cell Carcinoma REPLY
    Shiver, Mallory B.
    Mahmoud, Fade
    Gao, Ling
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (05): : 495 - 495